PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review
Donald C. Moore, Joseph B. Elmes, Justin Arnall, Scott A. Strassel, Jai N. Patel
Topics & Concepts
AtezolizumabAdverse Event Reporting SystemMedicineDurvalumabNivolumabPembrolizumabPharmacovigilanceAdverse effectInternal medicinePneumonitisImmunologyOncologyCancerImmunotherapyLungCancer Immunotherapy and BiomarkersHeparin-Induced Thrombocytopenia and ThrombosisPlatelet Disorders and Treatments